Her Excellency Amira Elfadil Mohammed Elfadil was elected the Commissioner for Social Affairs at the 28th Ordinary Session of the Assembly of the African Union in 2017. Before being elected as Commissioner she served the Government of the Republic of the Sudan as Minister of Welfare and Social Security between 2010 and 2013 and as Minister for Social Affairs for the Khartoum State Government between 2009 and 2010.
Head, Industrialisation, Science - Technology & Innovation, African Union Development Agency-NEPAD
Prof. Aggrey Ambali is currently serving as Head of Science, Technology and Innovation Hub (NSTIH) at the New Partnership for Africa's Development (NEPAD) Agency, where he oversees development and implementation of programs in education, health, and science and technology. He has also served in other positions at the NEPAD Agency, including Director of Policy Alignment and Program Development, Coordinator of the African Biosciences Initiative, and Coordinator of Science and Technology for the Southern Africa region.
Director General of the United Nations Industrial Development Organization (UNIDO)
LI Yong, Director General of the United Nations Industrial Development Organization (UNIDO), has had an extensive career as a senior economic and financial policy-maker. As Vice-Minister of Finance of the People’s Republic of China and member of the Monetary Policy Committee of the Central Bank for a decade, Mr. Li was involved in setting and harmonizing fiscal, monetary and industrial policies, and in supporting sound economic growth in China. He pushed forward financial sector reform, and prompted major financial institutions to establish corporate governance, deal with toxic assets and strengthen risk management. Mr. Li gave great importance to fiscal and financial measures in favor of agricultural development and SMEs, the cornerstones for creating economic opportunities, reducing poverty and promoting gender equality. He played a key role in China’s cooperation with multilateral development organizations, such as the World Bank Group and the Asian Development Bank.
Assistant Director General for Access to Medicines, Vaccines and Pharmaceuticals Cluster - WHO
Dr Mariângela Batista Galvão Simão from Brazil was most recently WHO Assistant Director-General for Drug Access, Vaccines and Pharmaceuticals. She was Director of Community Support, Social Justice and Inclusion at UNAIDS. In addition to her work at UNAIDS, she brings more than 30 years of experience working in the Brazilian public health system and has played an active role in enhancing access and decentralizing health services in the country.
Between 2006 and 2010, she served as Director of the National STD/AIDS and Viral Hepatitis Department in the Brazilian Ministry of Health, where she led successful price negotiations with pharmaceutical companies to lower the price of HIV medication. During this time, she also represented the Brazilian Ministry of Health in the negotiations that led to the constitution of UNITAID in 2006, including its governing body, where she served as a board member until 2008. She was trained as a paediatrician in Brazil and holds an MSc degree in public health from University of London, United Kingdom.
DG of Department of Trade and Industry of South Africa
Mr Lionel October was appointed Director-General of the Department of Trade and Industry from 21 April 2011.
Lionel October was appointed the Acting Director-General (DG) of the Department of Trade and Industry (the dti) in South Africa on 01 January 2011. Prior to his appointment as DG, he served as the Deputy Director-General (DDG) responsible for the enterprise and economic development portfolio, and served as an Economic and Trade diplomat at the South African Embassy in Brussels from 2007 to 2011. He was instrumental in key trade negotiations with the European Union.
Under his leadership as the DDG, the dti has spearheaded key industrial and enterprise development policies such as the National Industrial Policy Framework and Action Plan, and the development and implementation of Broad-Based Black Economic Empowerment legislation, to name a few.
Appointed as CEO of OCEAC in November 2017. OBIANG is well familiar with the management of community health programs and an astute academic. He studies in Spain and holds several degrees in Public Health.
Director General, Department of Health, South Africa
Ms Malebona Precious Matsoso is the Director General of the National Department of Health, having been appointed by the President of South Africa on 08 June 2010 to head the national office under the leadership of the Minister of Health Dr Aaron Motsoaledi and Deputy Minister of Health Dr Gwen Ramokgopa.
This puts her in charge of the South African Department of Health, managing health issues for the entire country and reporting to and advising the Health Ministry.Ms Matsoso holds a degree in Pharmacy from the University of Western Cape, a Postgraduate Diploma in Health Management from the University of Cape Town, and a Masters degree in Law and Ethics (LLM) from the University of Dundee. As a pharmacist she has worked in both the public and private sector at management level.
The Director-General was a Director in Public Health Innovation and Intellectual Property (PHI) in the office of the Director General, of the World Health Organisation (WHO) serving as WHO Secretariat on Public Health, Innovation and Intellectual Property.Her career within the field of medicine control have included posts as Head of Medicines Control Council (MCC), member of the National Research Ethics Council of South Africa, and the Director of the Essential Drugs and Traditional Medicines Programme for the South African Health Department as well as being a member of various advisory panels with an emphasis on improving access to medicines and antiretrovirals.
Prior to this she was the Registrar of Medicines of the National Drug Regulatory Authority in South Africa and has produced over 40 technical guidelines for the Authority, and served in various bodies including the Medicines Control Council (MCC) which she headed for seven years responsible for overseeing 10 technical committees.She has been a member of various advisory panels locally and internationally, mainly tasked with improving access to medicines. She also served as Secretariat of the Southern African Development Community (SADC) harmonization initiative and has coordinated related activities for the region for effective regulation of medicines in the region.
Tania Zulu Holt is a Partner at McKinsey. She started her career in the London office and subsequently re-located to Johannesburg in 2010, to pursue her passion for the continent and help expand McKinsey's activities in health care across Africa. She leads McKinsey's healthcare activities across Africa, motivated by a personal passion for extending access to affordable and high-quality healthcare services and products. She works at the intersection between private companies, governments and social stakeholders across the whole continent, and has on-the-ground experience across over 20 countries to date.
Tania is passionate about diversity in organizations–and is a co-author of McKinsey’s highly acclaimed “Women Matter Africa” report that shows that companies with a greater share of women on their boards of directors and executive committees tend to perform better financially.
Prior to joining McKinsey, she worked with the Danish Ministry of Health.
Margareth Ndomondo-Sigonda is Head of Health Programs at the African Union-New Partnership for Africa’s Development (NEPAD) Planning and Coordinating Agency since September 2016, where she served as Pharmaceutical Coordinator. She is responsible for the coordination of health and pharmaceutical programmes including the African Medicines Regulatory Harmonization Initiative, as part of the African Union Health Strategy and Pharmaceutical Manufacturing Plan for Africa. She has held several positions at the Ministry of Health and Social Welfare for Tanzania, serving as Chief Pharmacist (1998), Registrar of Pharmacy Board (1998-2003) and Director General of the Tanzania Food and Drugs Authority (2003-2010) .
Margareth holds an MSc degree in Pharmaceutical Services Management from the University of Bradford, UK and an MBA from the Eastern and Southern Africa Management Institute-Tanzania/ Maastricht School of Management, the Netherlands. She obtained her Bachelor’s degree in Pharmacy from the University of Dar es Salaam, Tanzania. Margareth is currently pursuing doctoral studies at the University of the Witwatersrand, Johannesburg, South Africa.
Nicolaou is currently responsible for strategic trade at the Aspen Pharmacare Group. Aspen is Africa’s largest and the world’s ninth largest generic pharmaceutical company by revenue ranking. Nicolaou has been instrumental in introducing the first generic antiretroviral medicines in Africa. These were developed by Aspen and saved many lives in South Africa and Africa.
Nicolaou has over 27 years of experience in the South African and international pharmaceutical industry and is a previous winner of the SA Institute of Marketing Management Healthcare Marketer of the year award, the most prestigious of its kind at the time. He was recently inducted as one of the youngest Fellows of the Pharmaceutical Society of South Africa (PSSA), which is one of the highest honours bestowed by the PSSA.
Nicolaou is the chairman of the Public Health Enhancement Fund, a collaboration between the private health sector and the Ministry of Health. He is also the chairman of
Pharmaceuticals Made in South Africa, an industry association of local pharmaceutical manufacturers that is made up of local South African producers and black empowerment companies.
Greg Perry joined IFPMA on 1st February 2018, and has responsibility for IFPMA’s external outreach and stakeholder engagement in global health topics including innovation, access, and the international regulatory environment. Greg Perry brought with him more than 20 years’ leadership and advocacy experience in the public healthcare arena.
Prior to joining IFPMA, Greg worked as Executive Director of the Medicines Patent Pool, which he joined in 2013 and as Director General of the European Generic Medicines Association (1999 - 2013) in Brussels. Previously he worked as a partner in a UK public affairs company as a European Union policy advisor to corporate and non-governmental organizations, and before that as a Parliamentary Advisor to Members of the European Parliament. Greg is a Member of the Advisory Council of the Organization for Professionals in Regulatory Affairs (TOPRA) and is a former member of the Standing Advisory Committee before the European Patent Office (SACEPO). Greg also holds the Golden Cross of Merit of the Republic of Poland.
Jayasree K. Iyer leads the Access to Medicine Foundation as Executive Director. She directs the Foundation’s strategy, its stakeholder dialogues and research programmes. As a spokesperson, she is actively involved in stimulating change within the pharmaceutical industry.
Jayasree joined the Foundation in 2013 to build up its in-house research expertise and to lead the development and application of its methodology for measuring company behaviour. She has worked at the interface of the global health community and the pharmaceutical industry for 12 years. Before joining the Foundation, Jayasree was responsible for creating, negotiating and managing public private partnerships in R&D for infectious diseases and oncology. She has worked at NGOs, academic institutions and think tanks, and holds various postgraduate degrees (Masters and PhD) from Singapore and the Johns Hopkins School of Hygiene and Public Health.
Ade Adebajo is an Economics graduate, a Fellow Chartered Accountant and a member of the Association of Corporate Treasurers.
Before joining Standard Chartered to set up the (London based) Africa Fixed Income unit in 2002 and subsequently head the Capital Markets origination team, Ade spent two years on the high yield/emerging markets desk at Tradition (UK) Ltd., with responsibility for African client origination.
Ade has financial services experience across areas including Project & Structured Finance, Corporate Finance, Asset Management and Private Equity. Having started as a trainee at Price Waterhouse in London, he subsequently worked within Risk functions at Gartmore Investment Management plc and
then as an Analyst on the Structuring Desk and Asset Development at Enron Capital & Trade Resources. He was Senior Manager, Energy Project & Structured Finance (European Investment Banking Division) at Bank of Tokyo-Mitsubishi before moving to the Capital Markets field.
Since 2000, Ade has worked exclusively on the African markets, originating, structuring and executing domestic and international transactions, including several award-winning bond issues and "firsts" in markets including Botswana, Ghana, Kenya, Nigeria, Tanzania, Uganda and Zambia. He is a frequent speaker and panellist on frontier economies, and has provided policy advice on developing African capital markets for central banks, multilateral agencies, municipals, regulatory authorities and other entities. He was also selected to present a paper on ‘Financing the 7-Point Agenda of the Federal
Government through the Capital Markets’ in Abuja, Nigeria. Apart from advising African focused banks and securities houses globally, he was also appointed in 2013 by the African Development Bank as part of a four-person External Advisory Panel for the African Infrastructure Financing Facility (“AIFF”
or “Africa50 Fund”). He was most recently a senior banker at Citigroup, London, working within the Institutional Client Group.
Alastair West is a senior technical advisor for UNIDO s pharmaceutical team. He holds a Bachelor s in Biochemistry from Oxford University and a MBA from IMD in Switzerland. He worked in the pharmaceutical and biotech industries for the first eight tears of his career. After his MBA he joined the World Bank as part of the vaccine team in Washington DC and later worked for the International Finance Corporation as Industry Expert for Life Sciences in the General Services and Manufacturing Division. He has been with UNIDO for six years and has worked on a number of pharmaceutical industry pro j ects in Africa. As part of this work he co-authored the Business Plan for the Pharmaceutical Manufacturing Plan for Africa (2012).
Bankole Eniola is the Director of Project ﬁnance for DFS Africa. He has over 12 years’ experience in investment banking and project financing in leading financial services organisations such as HSBC, UBS, Deutsche Bank, Lloyds Banking Group and Royal Bank of Scotland.
Bankole's ﬁelds of expertise include Deal Origination and Structuring, Strategic Planning, Risk Analysis, Financial Modelling, Transaction Structuring and Deal Execution. Bankole’s core deliverables over the last decade includes setting up several public‐private partnerships, design of public procurement processes in infrastructure financing, pricing and regulation of infrastructure services; public and private sector performance monitoring and macroeconomic and ﬁscal performance evaluation.
Bankole is one of the experts on the African Economic Platform (AEP) working on the region's 10-year strategic plan for infrastructural development. He also consults for the African Development Bank (AfDB) and he is a regular contributor to infrastructure financing dialogues on the continent.
Bankole has a Bachelors degree in Mechanical Engineering from University of Ado-Ekiti, Nigeria, a Masters degree in Infrastructure Financing from University College London and a MBA from Birmingham University.
Amit N. THAKKER is a medical doctor, a visionary entrepreneur, industry captain and ground-breaking pioneer in the integration of the private sector within the health system in Africa. He is currently the Executive Chairman of Africa Health Business and the Africa Healthcare Federation and a Director with AMREF Flying Doctors (Kenya) and Seven Seas Technologies. Dr Thakker received an Executive Master of Business Administration degree in 2007 from National Insurance Academy in India and a Bachelor of Medicine, Bachelor of Surgery degree in 1997 from the University of Nairobi. He was the 2017 recipient of the Best CEO award by Titans Global in the Business and Professional Services category, the 2004 Chairman’s Award by the Kenya Medical Association and the 1999 Best Male Entrepreneur of the Year award by Rotary International.
Morena joined Biovac in 2004 and holds the role of Chief Executive Officer. He is a member of the Board and the Biovac Executive team.
His mandate is to realise the objective of building vaccine manufacturing capacity in Southern Africa through:
Establishing strong links and partnerships with public-sector stakeholders as well as industry partners.
To ensure sound corporate governance as a responsible corporate citizen.
To spearhead the implementation of state of the art manufacturing facilities that are supported and guided by sound quality assurance, human capital expertise, regulatory licencing, business/product development and prudent financial management.
Strategic participation within the local and global vaccine landscape.
Morena is a medical graduate from the University of Cape Town (UCT) in South Africa and has participated in numerous executive courses including the Stanford Executive Program for Growing Companies (EPGC). Prior to his CEO role at Biovac he held the role of Deputy CEO and prior to that of Medical Affairs Director for Biovac and Litha Healthcare Group.
He serves on a number of committees within the vaccine industry and serves as a board member of other healthcare and non-healthcare companies.
Paul A. Lartey PhD, RPh serves as the Chief Executive officer and President of LaGray Chemical Company Ltd. and LaGray Chemical Company, Inc. Dr. Lartey has over 25 years of experience in research and management at Abbott Laboratories, Pharmacia & Upjohn and Pfizer. He founded LaGray Foundation for Tropical Diseases Research. Dr. Lartey serves as a Director of LaGray Chemical Company Ltd., and LaGray Chemical Company, Inc. He served as Director of Infectious Diseases Drug Discovery Research at Pfizer. Dr. Lartey has several patents and publications in drug discovery. Dr. Lartey has a Ph.D. in Medicinal Chemistry from the State University of New York at Buffalo and post-doctoral training in Medicinal Chemistry from Yale University.
Manager Public Health, Security and Nutrition, AFDB
Dr. Babatunde Omilola recently joined the African Development Bank (AfDB) to lead the Public Health, Social Protection and Nutrition Division of the Bank. Prior to joining AfDB, he served as the Head of Development Planning and Inclusive Sustainable Growth Team with the United Nations Development Programme (UNDP) in New York. In this position, he led.
Prior to joining UNDP, Dr. Babatunde Omilola worked with the International Food Policy Research Institute (IFPRI), Washington D.C., as the Africa-wide Coordinator and Program Leader of the Regional Strategic Analysis and Knowledge Support System. In the past, he worked with the Food and Agriculture Organization of the United Nations (FAO), where he handled FAO liaison functions with the African Union Commission (AU) and the United Nations Economic Commission for Africa (ECA) in Addis Ababa, Ethiopia. He has managed high-level policy and knowledge initiatives, intergovernmental processes and partnerships at national, regional and global levels.
Dr. Babatunde Omilola holds an M.Phil. and a Ph.D. in Development Studies and Development Economics respectively from the Institute of Development Studies (IDS), University of Sussex, United Kingdom where he studied as a Ford Foundation International Fellow. He has visited and carried out professional assignments in 87 countries worldwide, including countries in Africa, Middle East, North America, Europe, Latin America and the Caribbean and Asia and the Pacific.
Dr. Chris Reddick is Vice President, Medical Professional Affairs at Takeda Pharmaceutical Co., Ltd. He has spent nearly 20 years in the healthcare industry, working from bench to bedside, to bring new medicines to patients in need. As an advocate for patients, his professional and philanthropic work focuses on addressing issues of access to healthcare and medicines, health disparities, and patient-centered medicines development.
In 2012 he co-founded Healthcare Partners for Access, an organization dedicated to improving health outcomes for individuals living in poverty through innovative partnerships between healthcare companies and nongovernmental organizations.
Dr. Clet Niyikiza is the Founder, President and CEO of L.E.A.F. Pharmaceuticals LLC (L.E.A.F.) after serving as the Executive Vice President of Development at Merrimack Pharmaceuticals, Inc. from 2009 until 2014 where he was involved in the development and approval of ONIVYDE®, for the treatment of advanced pancreatic cancer.
In October 2016, Dr. Niyikiza and his team at L.E.A.F. received the 2016 Health Care Innovator Award in recognition of the company's leadership and innovation in the fight against cancer. The award honors the people and companies who are disrupting the health care and biotechnology industries and solidifying Greater Philadelphia's reputation as a center for innovation.
Since 2005, Dr. Niyikiza has been a member of President George H. W. Bush’s C-Change national forum dedicated to the advancement of cancer research, treatment and prevention. He is a member of the American Association for Cancer Research and the American Society of Clinical Oncology. A native of Rwanda and father of three children, Dr. Niyikiza holds a doctorate in Mathematics from Indiana University-Bloomington, Indiana, U.S.A., and is currently a member of the Presidential Advisory Council of Rwanda.
In addition to his passion for cancer research, Dr. Niyikiza’s other interests are designing and building homes for his family, and empowering and developing young scientists through research and collaborative initiatives.
Head, External Innovation, Global Public Health R&D - Janssen, Pharmaceutical Companies of Johnson and Johnson
Experienced in leading multiple functional areas and drug development programs in pharmaceutical R&D. Skilled in early and late stage drug development through drug registration. Strong business development skills through partnerships with external collaborators including Pharma companies, biotechs, not-for-profits and PDPs. Doctor of Philosophy (Ph.D.) focused in Toxicology and Pharmacokinetics from St. John's University.
Dr Gitahi joined Amref Health Africa on June 1, 2015. Until his appointment at Amref Health Africa, Dr Gitahi was the Vice President and Regional Director for Africa, Smile Train International, where he successfully established partnerships for long-term sustainability with various African governments. Prior to that he worked with the Nation Media Group, where he was the Managing Director for Monitor Publications in Uganda as well as General Manager for Marketing and Circulation in East Africa. He also held progressively senior positions at GlaxoSmithKline, Avenue Group and the insurance industry.
Dr Gitahi has a Bachelor’s degree in Medicine and Surgery and a Masters in Business Administration, majoring in Marketing.
Dr. Ifeanyi Okoye is a pharmacist with an M.Sc. and a Ph.D in pharmaceutical technology and industrial pharmacy (best graduating student in his class) as well as an Alumnus of the prestigious Harvard Business School, Boston, USA. Dr. Okoye founded Juhel in 1989, and it was the first tablet manufacturing company in Anambra State.
He is a fellow of the Pharmaceutical Society of Nigeria, a member of the national Institute (MNI), a memebr of the Governing Council of the Standard Organisation of Nigeria, as well as a member of the Governing Council of Federal Polytechnic Oko, having successfully attended the National Institute for Policy and Strategic Studies, Kuru, Plateau, Nigeria.
Dr. Okoye has also been awarded with the National Honour, Officer of the Order of the Federal Republic (OFR) by the President.
Dr. Okoye was the Vice President (National) of the Manufacturers Association of Nigeria (MAN) 2006-2010, and was Chairman, Board of Directors, General Cotton Mill, Onitsha from 2007-2009.
Dr. Dong is Programme Manager for Local Production, Regulatory Systems Strengthening (RSS), Regulation of Medicines and other Health Technologies (RHT), Department of Essential Medicines and Health Products (EMP) at the World Health Organisation (WHO) Headquarters.
Dr. Njeri Mwuara is a medical doctor and award winning public health specialist with wide experience and in-depth knowledge of the public and private sectors in Kenya and other developing markets in Africa. She has spearheaded and or collaborated on multiple high impact projects which impact on healthcare coverage and delivery. Currently, she is the Kenya Programme Lead, Health in Africa Initiative, Health, Nutrition and Population Global Practice, at the World Bank Group. Key achievements include development of the Kenya Health Bill, a regulatory framework on patient safety and quality of care and have been core in advancing the UHC agenda in Kenya.
Until this appointment in July 2017, Dr. Olajide served as the Chief, Non-Core Funds Management Unit in the Office of the Executive Director, UNFPA headquarters in New York since May 2015. At UNFPA, Dr. Ademola and his team worked in developing clear processes of allocation of non-core throughout the organization. This included determining allocation limits.
Until this appointment in July 2017, Dr. Olajide served as the Chief, Non-Core Funds Management Unit in the Office of the Executive Director, UNFPA headquarters in New York since May 2015. At UNFPA, Dr. Ademola and his team worked in developing clear processes of allocation of non-core throughout the organization. This included determining allocation limits for regions and countries to ensure better planning and co-ordination.
Dr. Olajide served as the UNFPA Representative in Namibia in 2014 where he spearheaded efforts in population data and evidence, while supporting interventions that enhanced reproductive health and gender equality.
Previously, he served as the Head of Division, Health, Nutrition and Population African Union Commission in Ethiopia from 2011 to 2013.
His earlier career was with UNICEF and UNFPA in Nigeria, where he held various positions such as Programme Adviser, Reproductive Health Adviser, National Programme Officer as well as HIV/AIDS Specialist.
Before joining the UN he served as the Executive Director, Group Medical Practitioners in Nigeria from 1995 to 2002.
Dr. Olajide holds a Doctor of Medicine degree from University of Ibadan, Master’s degree in Business Administration from Federal University of Technology, Master of Public Health from the University of Ibadan and Masters of Arts in International Relations from Benue State University.
Dr. Skhumbuzo Ngozwana – President & Chief Executive Officer. Dr Ngozwana is an internationally renowned African Pharma expert, who has served as a consultant to the World Health Organization (WHO), United Nations Industrial Development Organization (UNIDO), the Joint United Nations Programme on HIV/AIDS (UNAIDS) and the United States Pharmacopeia Convention (USP) among others. As the International lead consultant for UNIDO, Dr. Ngozwana co-authored the Pharmaceutical Manufacturing Plan for Africa that was adopted by the African Union heads of state and government in 2012.
The plan was the output of the extensive research and analytical work on the African pharmaceutical industry on behalf of UNIDO and the African Union Commission. His recent UN assignment was as part of an expert team of three appointed to develop the Ethiopian Pharmaceutical Sector Strategy and Action Plan. This document was adopted by the Ethiopian government as a blueprint for developing the Ethiopian sector; and is now incorporated into the Ethiopian Growth and Transformation Plan II.
r. Victor Moyo served as the Senior Consulting Medical Director of Diffusion Pharmaceuticals LLC until August 25, 2016. Dr. Moyo is an Oncologist/Hematologist with substantial experience in the development of novel therapeutic and companion diagnostic approaches to cancer. Prior to joining Diffusion Pharmaceuticals, he served as Vice President of Clinical Investigations at Merrimack Pharmaceuticals, providing clinical support for oncology programs including Pre-IND programs, First-in-Human, Phase 1 multi-arm safety and tolerability, and Phase 2 proof of concept, studies involving multiple programs. he has also supported registration studies with the USFDA and other regulatory agencies. Prior to Merrimack Pharmaceuticals, his experience includes service as Medical Director for Centocor-Ortho Biotech (Johnson and Johnson) and service as an Assistant Professor in the Department of Medicine, Division of Hematology/ Oncology, University of Connecticut Medical Center, in Farmington CT. Dr. Moyo also has experience conducting clinical research in south and central Africa and has published on various other topics including iron overload disorders and malaria. He is also a co-inventor of several patents involving the treatment of several cancers. He holds an MBChB degree from the School of Medicine, University of Zimbabwe, and did internships at Mpilo Central Hospital, Bulawayo Zimbabwe and The George Washington University Medical Center, Washington, D.C. where he also completed his Residency in Internal Medicine. He also completed a fellowship in Hematology and Oncology at Johns Hopkins Hospital in Baltimore, MD.
Mr. Sinhue B. Noronha holds Bachelors and MBA degrees from reputed Indian Universities and currently serves as the CEO and Founder of Africure Pharmaceuticals Ltd with a Vision of Helping Africa build self-sufficiency in Pharmaceuticals across key geographies, and a Mission of manufacturing high quality essential medication In Africa, By Africans, For Africa. Africure Currently has plants in Cameroon, Cote de Ivoire, Namibia, Botswana, India, and is setting up new plants in Ethiopia and Zimbabwe.
Prior to this he has spent 28 years in Pharmaceutical Industry at various level with about 12 years in the Indian Industry and 26 years in Managing African operations.
Akthem Fourati, MD, is the chief of Medicines and Nutrition Centre in UNICEF
Supply Division supporting the procurement of Medicines and Nutrition
products for Maternal and Child Health programmes. He joined UNICEF in
2006 and has mainly worked on Immunization, HIV/AIDS and Maternal/Child
Johnpaul Omollo is a public health professional with experience in health systems strengthening and health advocacy. I am currently the advocacy public policy research and development program officer at PATH, previously the National Coordinator of the Health NGOs Network (HENNET). I am an analytical and hard-working Health professional with practical hands-on approach, who always perseveres to achieve the best results. Able to collect and analyze information, digest facts and figures and quickly grasp complex technical issues.I have proven ability to manage and complete projects to the highest standard, with a meticulous attention to detail and within agreed deadlines.
Dr. Ibrahim Assane Mayaki of the Republic of Niger is the Chief Executive Officer of the New Partnership for Africa's Development (NEPAD) Agency. He was appointed to the position in January 2009.
A former Prime Minister of Niger, from 1997 to 2000, Dr. Mayaki has a Master' degree from the National School of Public Administration (Enap), Quebec, Canada and a PhD in Administrative Sciences from the University of Paris I, France.
Chairman Board of FAPMA
Emmanuel Mujuru is a qualified pharmacist, entrepreneur and business man with a passion for the development of local pharmaceutical production not only in Zimbabwe but in Africa in general. Emmanuel has been active in the pharmaceutical industry for the past 20 years during which he gained extensive experience in pharmaceutical production, research and development, quality assurance and marketing and distribution.
Mr. Kofi Adomakoh
Director, Project & Export Development Finance, African Export-Import Bank
Mr. Kofi Adomakoh holds a Bachelor of Science degree in Agricultural Economics and an Executive MBA from the University of Ghana. Mr Adomakoh worked for the Trust Bank of Ghana Limited from 1993 to 1997 in the Operations and Credit & Marketing departments. He joined Ecobank Ghana Limited in 1997 as a Senior Relationship Manager in the Institutional Banking Group, rising to become Head of the Institutional Banking Group in 2002. Mr Adomakoh joined the African Export-Import Bank in November 2009.
Currently supporting the formulation and implementation of Pricing and Access strategies for all Pfizer assets across Sub Saharan Africa Region. Supporting the business to craft commercially viable offers for retail, tenders, contract and other institutional customers. Strategically building relationship with key stakeholders to expand brands in the essential drug lists of payers and health insurance agencies.
Before this role, Muhammad was the Trade and Access Manager. During the time, supported the establishment of co-promotion contract with distributors and on-boarded suitable distribution partners in Ghana.
Before the role, he was the Key Accounts Manager-North. In that capacity, led the establishment of relationship with the customers that resulted in triple digit growth for three consecutive years.
Muhammad started as a Pharmaceutical Sales Representative covering the north west geopolitical zone. In the role, helped the company to grow the sales of products, recruited new customers and generally expanded the business.
Muhammad holds a Bachelors degree of Pharmacy from ABU Zaria, a Postgraduate Diploma and MBA from Bayero University, Kano.
Vibrant and energetic bilingual scientist and global health advocate/communicator with 20 years of experience within the United Nations leading the development and implementation of reproductive health evidence-based strategic policies, programmes and interventions in partnership with governments, the international community, civil society, researchers and the private sector.
Group Lead, Supply and Access to Medicines - WHO-HQ
Provide strategy and leadership to a diverse portfolio, promoting effective supply and access to medicines in emerging markets. Develop global policies and engage active partnerships.Continual improvement in medicines supply chains and emergency response.
Professor / Consultant, Clinton Foundation / Howard University
Joseph Fortunak, Ph.D., is an organic chemist. He spent 21 years in the pharmaceutical industry, most recently as head of global chemical development at Abbott Labs (2004). Joseph is a professor at Howard University specializing in green chemistry and global access to medicines. He works with organizations such as the World Health Organization, UNITAID, the Clinton Foundation, and the Kilimanjaro School of Pharmacy.
Prof Nelson Torto is the Executive Director of The African Academy of Sciences (The AAS). Under his leadership, the goals of The AAS are to promote partnerships, mobilise the African scientific community, lead science advocacy efforts and ensure research findings are incorporated into policymaking so that science remains at the forefront of the African agenda and is adequately supported to transform people’s lives. At the core of his agenda is empathy; the stakeholder has to be part of finding the solution to their challenges. Prior to joining The AAS, Prof Torto was the founding Chief Executive Officer of the Botswana Institute for Technology Research and Innovation. He has had an illustrious academic and research career and has graduated 19 PhD students during his tenure at the University of Botswana and Rhodes University. He is a Fellow of The African Academy of Sciences, Inaugural Fellow of the Botswana Academy of Sciences and a Fellow of the Royal Society of Chemistry (UK). He is a recipient of the Young Separation Science Award by the American Chemical Society.
Deputy Director, Tackling Infections to Benefit Africa (TIBA), University of Edinburgh
FProfessor Mutapi is a Professor in Global Health Infection and Immunity, co-Director of the Global Health Academy and Deputy Director of the NIHR Global Health Research Unit TIBA (Tackling Infections to Benefit Africa) at the University of Edinburgh. TIBA is an Africa-led, wide-ranging, multi-disciplinary research programme that explores and draws lessons from the ways that different African health systems tackle infectious diseases. TIBA aims to harness the expertise and technical capability in biomedical and social sciences at the University of Edinburgh and African partners to reduce the burden and threat of infectious diseases in Africa by informing and influencing health policy and strengthening health systems. Professor Mutapi currently sits on several international advisory boards and funding committees, including the African Academy of Science and NEPAD-AUDA’s advisory group and the WHO African Regional Director’s independent advisory group. She currently chairs the United Kingdom Department of Health’s National Institutes of Health Global Research (Groups) Funding committee and was recently appointed to the UK Research and Innovation Global Challenges Research Fund Strategic Advisory Group.
An effective business leader with extensive experience leading senior level strategic and cross-functional initiatives and building technology solutions and platforms that delight customers, optimize operations and improve bottom-line to position business for the next level of performance.
Innovator, problem-solver, result-oriented and entrepreneurial.
I am interested in entrepreneurial opportunities to leverage my expertise in technology, and business processes to develop frontier solutions catering to unmet market needs.
Program & Product Management
Six-Sigma/Kaizen/Lean Technique/Improvement tools & programs
Cloud Computing and Analytics
Internet of Things
Quality System Regulations, Process V&V (IQ/OQ/PQ), Design V&V, RCA, CAPA, FMEA
Regulatory Filings and Standards (510(k), PMA, 21 CFR part 820 21 CFR part 211, ISO 13485, ISO 14971, GxP, QA, RA)
Design Control/Risk Based Approach/ Quality Design
CEO & Co-Founder of Praedicare Laboratories. A company that has established itself as a leader in utilizing the hollow fiber system for optimizing drug regimens and dose selection in preparation of vertebrate animal studies and clinical trials.
Olakunle Olaniyi-Edwards advises on Corporate Finance transactions. His experience cuts across ﬁnancial sector, extractive industries and Public Sector ﬁnancing. His ﬁeld of expertise hinges on core understandings of Financial theories (Risk, Returns (Expected and Actual), Capital Allocation, Capital Structure, Pricing and Valuation), Financial Markets (Cash/Money, Equity, Debt and Derivatives markets), and Financial products (Cash, Equity, Debt and Derivatives).
His core skills are creating ﬁnancial models on well researched assumptions and data, analyzing core ﬁnancial statements, create pro‐forma artifacts, core valuation of companies, transaction origination, stakeholder management and corporate governance advisory.
He’s particularly keen on the social developmental effect of a well functioning market with good price discovery, transparency and deep liquidity pools, and the dent it makes on poverty. He has worked on numerous projects within leading Investment Banks such as HSBC, Barclays Capital and Lloyds Banking Group.
Kunle has a bachelor’s degree in Biochemistry from the University of Ibadan and attended executive courses in Investments and Capital Markets at Harvard University, USA.
Private Equity and Impact Investing Activities, DFS Africa
Olukayode Yemi Afolabi leads DFS Africa’s Private Equity and Impact Investing activities. In his role he curates platforms such as the Deal Room, Deal Portal and Investor Roundtables to fast track the deal making process in Africa. Kayode’s expertise is in Deal Structuring, Raising Capital, Board Governance and Operational Management to turn around financially distressed or undervalued companies and maximize shareholder value.
Prior to co-founding DFS Africa, Kayode worked with leading Investment Banks and FTSE 100 multinationals such as UBS, HSBC, Columbia-Threadneedle and British Telecoms leading large scale revenue-generating and regulatory programs.
Kayode has a bachelor’s degree in industrial chemistry from the University of Ilorin Nigeria and has attended several executive level courses at Harvard University and SAID Business School (University of Oxford) covering subjects such as Project Financing, Investments & Portfolio Analysis and Entrepreneurship.
Kayode’s professional mission is to make a significant and sustainable contribution to socio-economic development in Africa.